irbesartan actavis 150 mg
actavis group ptc ehf., island - irbesartan - 58 - hypotensiva
irbesartan actavis 300 mg
actavis group ptc ehf., island - irbesartan - 58 - hypotensiva
eplerenone actavis 50 mg
actavis group ptc ehf., island - eplerenón - 50 - diuretica
eplerenone actavis 25 mg
actavis group ptc ehf., island - eplerenón - 50 - diuretica
ferro-folgamma
wÖrwag pharma gmbh & co.kg, nemecko - Železo, vitamín b12 a kyselina listová - 12 - antianaemica
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresíva - pozrite si dokument s informáciami o produkte.
alopurinol sandoz 300 mg
sandoz pharmaceuticals d.d., slovinsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica
alopurinol sandoz 100 mg
sandoz pharmaceuticals d.d., slovinsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica
dolgit krém
dolorgiet gmbh & co. kg, nemecko - ibuprofen - 29 - antirheumatica, antiphlogistica, antiuratica
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukémia, lymfocytárna, chronická, b-bunka - antineoplastické činidlá - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.